BamSEC and AlphaSense Join Forces
Learn More

Tempest Therapeutics Inc. – Material Contracts

NASDAQ: TPST    
Share price (6/3/26): $1.27    
Market cap (6/3/26): $18.8 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.3
from 8-K 22 pages Placement Agent Common Stock Purchase Warrant Tempest Therapeutics, Inc
12/34/56
EX-10.2
from 8-K 22 pages Common Stock Purchase Warrant Tempest Therapeutics, Inc
12/34/56
EX-10.1
from 8-K 12 pages Holder of Common Stock Purchase Warrants Issued in November 2025 Re: Inducement Offer to Exercise Common Stock Purchase Warrants Issued in November 2025 Dear Holder
12/34/56
EX-10.4
from 10-Q 4 pages Material contract
12/34/56
EX-10.3
from 10-Q 7 pages November 19, 2025 Tempest Therapeutics, Inc. 2000 Sierra Point Parkway Suite 400 Brisbane, Ca 94005 Attention: Stephen Brady Re: Funding Commitment Ladies and Gentlemen
12/34/56
EX-10.29
from 10-K 9 pages February 3, 2026 Nicholas Maestas [Address on File] Re: Executive Employment Agreement
12/34/56
EX-10.28
from 10-K 10 pages November 19, 2025 Matthew Angel, PH.D. via Email Re: Executive Employment Agreement Dear Matthew
12/34/56
EX-10.27
from 10-K 14 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That Tempest Therapeutics, Inc. Treats as Private and Confidential Amended and Restated Master Services Agreement Section 1. Services
12/34/56
EX-10.26
from 10-K 31 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That Tempest Therapeutics, Inc. Treats as Private and Confidential Amended and Restated License and Collaboration Agreement Section 1 Definitions
12/34/56
EX-10.25
from 10-K 31 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That Tempest Therapeutics, Inc. Treats as Private and Confidential Exclusive License and Collaboration Agreement Section 1 Definitions
12/34/56
EX-10.12
from 10-K 3 pages Amendment No. 1 to Tempest Therapeutics, Inc. Amended and Restated 2023 Equity Incentive Plan
12/34/56
EX-10.2
from 8-K 28 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 43 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 7 pages Lock-Up Agreement
12/34/56
EX-10.1
from 8-K 80 pages Asset Purchase Agreement by and Between Erigen LLC, Factor Bioscience Inc. and Tempest Therapeutics, Inc. Dated as of November 19, 2025
12/34/56
EX-10.7
from 10-Q 6 pages August 8, 2025 Justin Trojanowski Re: Tempest Employment Terms Dear Justin,
12/34/56
EX-10.6
from 10-Q 5 pages Tempest Therapeutics, Inc. Success Bonus Agreement
12/34/56
EX-10.5
from 10-Q 8 pages June 13, 2025 Nicholas Maestas Re: Separation Agreement
12/34/56
EX-10.4
from 10-Q 8 pages June 13, 2025 Sam Whiting, M.D., PH.D. Re: Separation Agreement
12/34/56
EX-10.3
from 10-Q 8 pages June 13, 2025 Stephen R. Brady Re: Separation Agreement
12/34/56